A/Prof Olalekan O. Oluwole specializes in the treatment of hematological malignancies using stem cell transplantation and cellular therapy. He founded the Vanderbilt-Ingram Cancer Center (VICC) cellular therapy research program, and designed the nascent Vanderbilt initiative to expand cell therapy as an institution-wide resource for malignant and non-malignant disorders.

His primary field of research is in improving the safety profile of cellular therapy through investigator-initiated intervention trials, multi-institution sponsored therapeutic research and national consortium outcomes research. He led sponsored research showing the benefit of prophylactic corticosteroids during chimeric antigen receptor (CAR) T cell treatment and led a coalition of experts to publish a reference guide for outpatient CAR-T therapy. He is deeply invested in community engagement efforts to safely transition CAR-T to the outpatient setting. He is very active in the American Society for Transplant and Cell Therapy (ASTCT) where he is a member of the board of directors. He is a member of many committees including of the ASTCT Committee on Cellular Therapy and Committee on Practice Guidelines. He is board certified in internal medicine, hematology and medical oncology.